ArticlePharmaceuticals (Basel, Switzerland)2024

The Efficacy, Safety, and Persistence of Therapy after Non-Medical Switching from an Originator Adalimumab in Inflammatory Bowel Disease: Real-Life Experience from Two Tertiary Centres.

Teodora Spataru et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.